Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10396MR)

This product GTTS-WQ10396MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10396MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13336MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ13362MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ15240MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ12747MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ4357MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ8487MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ11293MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ15329MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW